Texas has committed $50 million in state funds to study ibogaine as a treatment for opioid addiction, PTSD, and related conditions — the largest state-funded psychedelic research initiative in U.S. history. The legislation passed both chambers of the Texas Legislature with bipartisan support and now awaits the governor’s signature ahead of the June 2025 C.E. session deadline, authorizing supervised clinical trials of a powerful plant-derived compound that federal scheduling has kept largely off-limits for decades.
At a glance
- Ibogaine research funding: Texas approved $50 million for FDA-aligned clinical trials through the Texas Ibogaine Initiative, paired with a matching $50 million contribution from a participating drug developer — bringing the total potential investment to $100 million.
- Target populations: The program prioritizes military veterans and first responders, groups with high rates of treatment-resistant PTSD and opioid use disorder who have increasingly sought ibogaine treatment at offshore clinics.
- Ibogaine origins: The compound is derived from the root bark of Tabernanthe iboga, a shrub native to Central Africa used in Bwiti spiritual and healing traditions for generations — a history that mainstream research discussions rarely center.
An unlikely champion for psychedelic research
The vote in Austin produced one of the more surprising political moments of the 2025 C.E. legislative session. Rep. Mike Olcott (R), a former biochemist and self-described fiscal conservative from the 60th District, stood before his colleagues and announced he was voting yes on HB 3717 — the ibogaine research bill — despite having voted no just two weeks earlier on a smaller, $1 million study into psilocybin, ketamine, and MDMA.
What changed his mind was a conversation with Amber and Marcus Capone, co-founders of Veterans Exploring Treatment Solutions (VETS), during a reception organized by the Texas Public Health Committee. The Capones have become among the most effective advocates for ibogaine research in the country, drawing on Marcus’s firsthand experience as a former Navy SEAL who sought treatment abroad.
“If I hadn’t served on the public health committee, I’d probably be a ‘no’ on this bill,” Olcott said of HB 3717. “$50 million dollars to play around with some psychedelic drug? That would go against every principle I have.”
He voted yes anyway. That shift — from a budget hawk with a Ph.D. in biochemistry, in a deeply conservative state — signals something real about where ibogaine research now stands politically.
Why ibogaine, and why now
Ibogaine occupies a strange position in American medicine. It is federally classified as a Schedule I substance with no accepted medical use, yet a growing body of peer-reviewed research points to its potential to interrupt opioid dependence after a single treatment session. A landmark 2023 C.E. study published in Nature Medicine, led by researchers at Stanford University School of Medicine, found that a single dose of ibogaine — administered under medical supervision in Mexico, where it is legal — dramatically reduced PTSD, depression, and alcohol use in U.S. Special Operations veterans. Disability ratings dropped by an average of 88 percent at one-month follow-up.
No existing FDA-approved drug comes close to those outcomes for this population.
The federal scheduling barrier has made it nearly impossible to conduct the large, controlled trials needed to translate that promise into clinical practice. Texas is now betting $50 million — with a potential $50 million match — that state funding can cut through that bottleneck. The Texas Health and Human Services Commission would oversee distribution of funds to research institutions running supervised clinical trials, with the explicit goal of generating the safety and efficacy data required for eventual FDA approval.
Rep. Cody Harris, who sponsored HB 3717, made the case in urgent terms on the House floor. “Ibogaine isn’t just another drug, it is a whisper of redemption,” he told colleagues. “In a single dose it can silence the screams of withdrawal, quiet the cravings that chain people to addiction, and mend the pieces of a mind ravaged by trauma… This isn’t a distant dream, it’s happening now just beyond our borders, and Texas can bring it home.”
The roots of this moment
The Texas Ibogaine Initiative grew directly from a 2023 C.E. effort in Kentucky, where advocates pushed the state’s Opioid Abatement Advisory Commission — which held over $842 million in pharmaceutical settlement funds — to allocate $42 million for ibogaine research. That effort stalled amid political opposition and concerns about ibogaine’s known cardiac risks, particularly its tendency to prolong the QT interval in ways that require careful medical screening. The same coalition regrouped and brought a larger, more structured proposal to Texas.
The Bwiti people of Gabon and Cameroon have used iboga in initiation and healing ceremonies for generations. Western researchers first isolated ibogaine in the early 20th century C.E., and American addiction scientists began studying it seriously in the 1960s C.E. before federal drug scheduling shut that work down. Some Indigenous and African scholars have raised questions about how the global psychedelic medicine industry engages with iboga’s origins — including issues of benefit-sharing and intellectual attribution. The Texas legislation does not address those questions directly, and they remain unresolved as the program moves forward.
For veterans, the stakes are acute. The U.S. Department of Veterans Affairs estimates that approximately 17 veterans die by suicide every day. Conventional PTSD treatments fail a significant portion of those who try them. Ibogaine’s mechanism — which appears to reset certain neural pathways rather than simply manage symptoms — represents a fundamentally different therapeutic approach, one that organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) have spent decades trying to bring into regulated clinical settings.
A signal beyond Texas
Texas may also become the first state to bring multiple psychedelic research bills to a governor’s desk in a single legislative session. Alongside HB 3717, HB 4014 — a broader $1 million study into ketamine, MDMA, and psilocybin therapies — passed the House and moved to the Senate. A third bill, HB 4813, proposes to automatically reschedule any drug the FDA deems safe or that the federal government removes from the controlled substances list.
The bipartisan coalition behind this legislation is built primarily on veterans’ advocacy rather than progressive drug policy. That political foundation may prove more durable — and more replicable in other states — than the frameworks that have driven psychedelic reform elsewhere. Researchers at the Johns Hopkins Center for Psychedelic and Consciousness Research and Stanford have argued publicly that removing research barriers is a matter of scientific urgency. Texas’s move may accelerate federal reconsideration of ibogaine’s scheduling — a conversation that has already begun within the FDA’s Breakthrough Therapy program.
The cardiac risk question still needs to be resolved through exactly the kind of rigorous, medically supervised trials this funding is designed to support. Whether the program’s safety protocols prove robust enough will be as important as the science itself. But $50 million in state-backed, clinical-grade investment moves ibogaine research from the margins to the mainstream in a way few developments in recent years have matched.
Read more
For more on this story, see: Lucid News
For more from Good News for Humankind, see:
- Indigenous land rights get a major boost ahead of COP30
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana’s marine protected area — the country’s first ever — marks a historic turning point for a nation gripped by a quiet fisheries crisis. Established near Cape Three Points in the Western Region, the protected zone restricts or bans fishing activity to allow severely depleted fish populations to recover. Ghana’s coastal stocks have fallen by an estimated 80 percent from historic levels, threatening food security and the livelihoods of millions of small-scale fishers. The declaration also carries regional significance, potentially inspiring neighboring Gulf of Guinea nations to establish coordinated protections of their own.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
